Interferon lambda-1 (IFN-l1/IL-29) is a member of the Type-III interferon family, which contains three ligands: IFN-l1, 2 and 3. These three ligands use the same unique heterodimeric receptor composed of CRF2-12 (IFN-l-R1/IL-28Ra) and CRF2-4 (IL10-R-b) chains. Like their close relatives, the Type-I interferons, IFN-l1, 2 and 3, promote the phosphorylation of STAT1 and STAT2, induce the ISRE3 complex, elevate OAS and MxA expression and exhibit antiviral activity in vitro. Their use of the IL10-R-b chain and their ability to phosphorylate STAT3, STAT4 and STAT5 suggested that they may also exhibit immunomodulatory activity; their antiviral action led us to hypothesize that this activity might be directed toward the Th1/Th2 system. Here, we have demonstrated that IFN-l1 altered the activity of Th cells in three separate experimental systems: (i) mitogen stimulation, (ii) mixed-lymphocyte reaction (MLR) and (iii) stimulation of naive T cells by monocyte-derived dendritic cells (mDC). In Con-A stimulation assays, the inclusion of IFN-l1 consistently led to markedly diminished levels of secreted interleukin (IL-13) with occasional coincident, modest elevation of secreted IFN-g. IL-13 secretion was 100-fold more sensitive to IFN-l1 than was IFN-g secretion. These observations were also made in the allogeneic two-way MLR. IFN-l1 was able to alter cytokine-mediated Th biasing and when naive T cells were exposed to allogeneic mDC that had been matured in the presence of IFN-l1, secreted IL-13 was again markedly and consistently reduced, whereas secreted IFN-g was largely unaltered. These functions were independent of IL-10. Our data support a hitherto unsuspected role for IFN-l1 in modulating the development of Th1 and Th2 cells, with an apparent emphasis on the diminution of IL-13 secretion.
Introduction
The discovery of the CRF2-12 receptor chain through its similarity with the external domain of the interleukin (IL)-22 receptor alpha chain (G Gallagher, unpublished observations) and its pairing with an orphan ligand, described as 'similar to type-one interferon', 1 led to the discovery and characterization of the interferon lambda (IFN-l) family members and their receptor in our laboratories 2 and in parallel elsewhere. 3 This is a new family of interferons related to both the IL-10 family of ligands and the Type-I and Type-II interferon family. Although they share functional characteristics with members of the intronless IFN-a family, the IFN-l genes have an intron/exon structure identical to members of the IL-10 family.
There are three ligands in the family: IFN-l1, 2 and 3 (known alternatively as IL-29, IL-28A and IL-28B, respectively 3 ). The ligands were termed 'Type-III Interferons' by the nomenclature committee of the International Society for Interferon and Cytokine Research. All three ligands can signal through the same heterodimeric receptor composed of CRF2-12 (IFN-l-R1/IL-28Ra) and CRF2-4 (IL10-R-b) chains. This receptor pair is not used by any other known ligand, although the CRF2-4 chain is also part of the IL-10, IL-22 and IL-26 receptors. [4] [5] [6] [7] Binding of the IFN-l ligand to its receptor initiates signaling reminiscent of the Type-I interferons. In particular, STAT2 is phosphorylated, ISGF3 is activated and OAS and MxA are induced. 2 These observations, in conjunction with the induction of the IFN-l1/2/3 ligands by a range of viral infections and their ability to rescue virally infected cells, 2, 3 have prompted a series of studies that have further investigated the antiviral properties of these cytokines. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, the IFN-l ligands also induce the phosphorylation of STAT1, STAT3, STAT5 2, 22 and STAT4. 23 Phosphorylation of STAT1, STAT3, STAT5 in particular, suggests more complex properties for the IFN-l ligand family; STAT3 is the signaling mechanism used by members of the IL-10 family (IL-10, IL-19, IL-20, etc. [24] [25] [26] [27] ), whereas STAT5 is used widely by cytokines, such as IL-2, IL-3 and granulocyte-macrophage colony stimulating factor (GM-CSF). [28] [29] [30] [31] [32] STAT4 is the signature-signaling molecule of the Th1 response, a process which is complemented by STAT1 signaling; [33] [34] [35] [36] thus, IFN-l1 may be able to alter the Th1/Th2 balance.
We, therefore, decided to investigate T-cell regulation by IFN-l. Our data demonstrate that IFN-l1 is capable of downregulating IL-13 secretion (the Th2 response); in some experimental environments, this is accompanied by a coincident, and more modest, elevation of IFN-g secretion (the Th1 response). The ability of IFN-l to influence IL-13 secretion may be of direct relevance to the pathogenesis and treatment of asthma. 37 
Results

IFN-l1 modulates cytokine secretion following mitogen stimulation
We investigated whether IFN-l1 could influence T-cell responses. First, we examined the effect of IFN-l1 on the production of T-cell cytokines IFN-g (representative of Th1 responses) and IL-13 (representative of Th2 responses) following Con-A stimulation. The experimental results are shown in Figure 1 . IFN-l1 consistently reduced IL-13 secretion (15/16 donors), often with no effect on IFN-g levels, across a range of concentrations of Con A (Figure 1a ). Occasionally (in only 5/16 donors), coincident-increased secretion of IFN-g was observed (as in Figure 1b ). These effects were IFN-l1 dose-dependent. Relatively high concentrations of IFN-l1 were required to elevate IFN-g levels (as has been previously observed for its antiviral activities 2, 3, 12 ). However, reduction of IL-13 consistently occurred at 100-fold lower concentration than that required to increase IFN-g (Figure 1c) . Furthermore, the ability of IFN-l1 to modulate IL-13 secretion was eliminated by proteinase-K treatment of this ligand before its addition to the cultures, demonstrating the effect was not mediated by some lipopolysaccharide (LPS)-like contaminant in our commercial (Peprotech, Rocky Hill, NJ, USA) IFN-l1 preparation (Figure 1d) . Thus, IFN-l1 primarily inhibits the production of IL-13, although in some cases, perhaps reflecting intraindividual variation, elevated secretion of IFN-g may occur at higher IFN-l1 concentrations. However, even when effects on IFN-g are observed, IL-13 is much more sensitive to the effects of IFN-l1.
IFN-l1-mediated reduction of IL-13 secretion is apparently independent of the actions of IL-10 IL-10 is a multifunctional cytokine known for its immunomodulatory capabilities. The lambda interferons use a receptor, which employs the IL-10-Rb chain, CRF2-4. We have recently demonstrated that IFN-l1 will elevate IL-10 levels in in vitro cultures of human peripheral blood mononuclear cells (PBMCs) and that endogenous IL-10 can moderate IFN-l1-induced responses. 38 We wished to see whether the ability of IFNl1 to reduce IL-13 secretion was influenced by IL-10. As shown in Figure 2a , the anti-IL-10 antibody elevated the secretion of IL-13, suggesting that endogenous IL-10 in the cultures was controlling IL-13 secretion. When IFN-l1 was added in the presence of anti-IL-10 antibody, IL-13 secretion was reduced (Figure 2b ), demonstrating that the effects of IFN-l1 were independent of IL-10.
IFN-l1 diminishes IL-13 and elevates IFN-g secretion in the two-way MLR
We wished to determine whether IFN-l1 could influence an assay that was dependent on T-cell receptor triggering. Accordingly, we investigated the ability of IFN-l1 to modulate Th1/Th2 cytokine secretion in the two-way mixed-lymphocyte reaction (MLR). As shown in Figure 3a , introduction of IFN-l1 led once again to a decrease in IL-13 secretion, with an accompanying increase in IFN-g secretion, at day 6 of the reaction (7/7 donors). Thus, IFN-l1 influences the developing T-cell response and the nature of the Th1/Th2 balance in this system also. As far as is currently known, all three lambda interferons use the same heterodimeric receptor. 2, 3 We tested IFN-l2 in the MLR assay and showed that it behaved similarly to IFN-l1, diminishing IL-13 and elevating IFN-g (Figure 3b ), as expected.
IFN-l1 diminishes IL-13 secretion in naive T cells following exposure to allogenic mDC
The ability of IFN-l1 to influence T-cell biasing was investigated. We developed dendritic cells (DC) from peripheral CD14 þ monocytes (monocyte-derived dendritic cells, mDC), using GM-CSF and IL-4 (Peprotech) and used them to stimulate naive allogeneic T cells. These T cells were then expanded in medium containing IL-2 and stimulated to secrete cytokine by treatment with phorbol myristate acetate (PMA) þ ionomycin, to indicate their overall Th1/Th2 development. At the time of exposing the T cells to the mDCs, three sets of conditions were introduced to influence the nature of the developing Th1/Th2 response: 'Th1 biasing', where IL-12 and anti-IL-4 were introduced; 'Th2 biasing', where IL-4 and anti-IL-12 were introduced and 'Th0 biasing', where both anti-IL-4 and anti-IL-12 were introduced. A 'no biasing' control in the absence of cytokines or antibodies was also used. The ability of IFN-l1 to influence these four T-cell biasing experiments was examined.
As anticipated, Th1 biasing conditions led to higher levels of IFN-g secretion, Th2 biasing to elevated IL-13 secretion and Th0 conditions to an intermediate secretion pattern (Figure 4a ). When IFN-l1 was introduced to this system (Figure 4b ), IL-13 was markedly diminished in each of the four test conditions, except in those of Th2 biasing. This indicates that, although IFN-l1 is generally able to diminish IL-13 secretion, it may not compete efficiently with IL-4's ability to promote the IL-13 response under the conditions employed here. There was little, if any, effect on IFN-g secretion in these experiments as noted previously, even though the highest dose of IFN-l1 (1000 ng/ml; Figure 1c ) was used. Notably, IFN-l1 did not appear to be able to replace IL-12, as there was no elevation of IFN-g secretion in the Th0-or Th2-biasing conditions, nor could it augment IL-12 effects in the Th1-biasing or no-biasing control. Thus, IFN-l1 is able to alter the Th1/Th2 development of naive human T cells, under antigen-driven conditions, by diminishing the development of Th2 cells and lowering the secretion of IL-13.
IFN-l1 alters the functional capability of mDC
The data presented above suggest that IFN-l1 may directly affect developing T cells while they are interacting with the stimulating mDC or that it may alter mDC function. We were interested in determining whether it was able to alter the stimulatory profile of mDC. First, we induced mDC from peripheral blood monocytes using As shown in Figure 5b , T cells, challenged (in the absence of IFN-l1) with allogeneic mDC (allo mDC) developed in the presence of IFN-l1, secreted much less IL-13 than those whose mDC had not been exposed to IFN-l1 during their development. IFN-g secretion was not affected. Thus, IFN-l1 is capable of changing the development of mDC in a way that results in their causing diminished Th2 development without enhancing their capability to develop Th1 cells.
Discussion
Recently, our laboratory and others discovered and presented the initial characterization of a new family of cytokines, the 'interferon lambda' family, IFN-l1/2/3.
2,3
These cytokines (also known as IL-29, IL-28A and IL-28B, respectively) were recently defined as 'Type-III' interferons. They share many of the antiviral properties of the Type-I interferons and have subsequently garnered particular interest as agents with activity against hepatitis viruses. 11, 14, 39 However, they may not be as efficient antiviral agents as the Type-I interferons. 3, 12 In addition to their interferon-like antiviral properties, the lambda interferons share a number of signaling and downstream events in common with the Type-I interferons. Notably, IFN-l1 signaling involves the phosphorylation of STAT2, considered a defining characteristic of Type-I responses. 40, 41 Furthermore, interferon response genes such as MxA and 5 0 3 0 OAS are activated 2 and subjected to typical regulatory mechanisms. 11 Although the IFN-l receptor is widely expressed, 2, 3 expression of the ligand is tightly controlled and takes place after viral infection 2, 17 or stimulation via many of the Toll-like receptors (TLRs), 15 a process that is elevated by IFN-a. 42 Expression via stimulation of TLR 7, 8 and 9 IFN-k1 downregulates the human Th2 response WJ Jordan et al is absolutely dependent on IRAK-4 signaling, whereas IFN-l1 can be transcribed following stimulation of the cell via TLR 3 or 4 in an IRAK-4-independent manner. 15 This expression following cell triggering by such a wide range of TLR molecules, together with the broad range of STAT molecules activated, suggests a broader role for IFN-l1, particularly in the response to intracellular infection.
IFN-l1 is expressed in both mDC and plasmacytoid dendritic cells (pDC). Following virus infection, IFN-l1 mRNA is present at approximately 100-fold greater levels in pDC compared with mDC. 8 The expression pattern in these cells resembles that of IFN-b rather than IFN-a. In pDCs, there is coordinated regulation of IFN-l1 and IFN-b expression. 8 Thus, there may be a role for IFNl1 in coordinating overall postinfection adaptive immune responses, both within DCs and in interfacing T cells. The experiments reported here address this latter question.
We have shown that IFN-l1 modulates the ability of T cells to secrete Th1 or Th2 cytokines. Both mitogendriven systems and MLRs showed strong skewing against Th2 responses in the presence of IFN-l1. The secretion of IL-13 was consistently and markedly diminished, whereas that of IFN-g was enhanced, although less frequently. These effects were doseresponsive to IFN-l1 but importantly, the effect on IL-13 was stronger and more consistent. IFN-l1 diminished IL-13 levels at an approximately 100-fold lower concentration than that required to bring about elevation of IFN-g. Furthermore, it was more consistent. For example, in the case of Con-A stimulation, the suppression of IL-13 was observed in 15/16 separate experiments, but the effect on IFN-g was seen in only 5/16 experiments (data not shown). Further evidence to support a primary role of IFN-l1 in downregulating Th2 responses rather than in promoting Th1 responses is shown in Figure 4 , where IFN-l1 was unable to elevate IFN-g levels in the presence or absence of IL-12 and thereby being clearly distinguishable from the actions of IFN-g, notwithstanding its ability to phosphorylate STAT1 and STAT3. 2 Thus, we postulate that they combine with those data to provide a picture of IFN-l1 activity that is more strongly anti-Th2 than pro-Th1. We do not yet know whether the modulation (or lack thereof) of IFN-g by IFN-l1 is consistent within the same individuals. Experiments are currently underway to address this issue, which may indicate an important genetic variation between individuals.
When we examined direct effects on either the induction or maturation phases of mDC production, we observed apparently distinct responses to IFN-l1. Its presence during the maturation phase (Figure 5a ) led to the production of mDC with modestly enhanced IL-12 secretion, whereas its presence during the induction phase (Figure 5b ) led to mDC with the ability to diminish IL-13 secretion from exposed allo T cells, with no effect on IFN-g production. At present, we can only speculate on the potential role of this slight increase in IL-12 production by mDCs. A recent report 43 described the inability of IFN-l1 to lead to the development of a mature DC phenotype, producing instead an intermediate phenotype, described as 'tolerogenic'; our data would not contradict this report. Clearly, however, it does not interfere with the ability of IFN-l1 to inhibit IL-13 secretion from T cells stimulated by mDCs and we believe it is likely that the major role of IFN-l1 is on the development of monocytes to intermediate DCs rather than on the final maturation of these cells.
Further work is be necessary in this area. Taken together, however, the diminished secretion of IL-13 by T cells stimulated with alloantigen in the presence of mDCs induced with IFN-l1 supports the altered cytokine levels seen in the T-cell priming, MLR and Con-A experiments (where IFN-l1 was present throughout the experiment). This positions IFN-l1 as a new modulator of the Th1/Th2 system, whose overall function in our experiments is to diminish Th2 responses. The mechanisms that underlie this Th2 modulation by IFN-l1 are currently unknown to us and will require further experimental effort to unravel. Interestingly, Type-I interferons are known to be capable of diminishing the expression of IL-4-dependent genes through upregulation of SOCS-1. 44 It may be that IFN-l1 is acting as a Type-I interferon to effect the Th2 modulation we report here. Its ability to activate STAT4 23 and modestly enhance IL-12 secretion (this report) also suggests some possible direct, Th1 stimulating effects, although it may be that the counterregulation of Th2 responses by these mediators is more important, given the stronger and consistent inhibition of IL-13 secretion by IFN-l1.
A recent report 37 described diminished expression of IFN-l1 mRNA in asthma patients following in vivo challenge with rhinovirus and in vitro challenge of their leukocytes with LPS. IL-13 and the Th2 system are recognized as a key mediator in the pathogenesis of bronchial asthma 45, 46 and its mechanism of action and means of control are of interest as new therapeutic targets. 47 IL-13 mRNA and protein are expressed in the lungs of allergen-challenged human volunteers 48 and asthma patients, 49 and its effect appears to be mediated via elevating the expression of MHC class-II and CD40 on CD11c-high alveolar DCs. 50 In experimental asthma models, airway hyperreactivity accompanied by high levels of IL-4 and IL-5 secretion can be induced in intact but not IL-13À/À mice. 51, 52 Sensitized animals can be protected by treatment with IL-13Ra-chain constructs, 53 and although the IL-4Ra-chain may be involved, this is disputed. 46, 49 Mice whose Th1 system is crippled by the genetic disruption of T-bet expression develop spontaneous asthma-like disease, which is accompanied by high numbers of CD44 and CD69 bright CD4 þ T cells; again, this condition can be ameliorated by the direct blockade of IL-13. 54 In humans, allergen-specific T-cell clones produce IL-13, 55 and IL-13 will elevate mast-cell proliferation;
56 experimental anti-Th2 strategies which do not address IL-13 have failed. 57 The IL-13 locus, which is ethnically very diverse, 58 is recognized as contributing to asthma susceptibility. 59, 60 Thus, as elevated IL-13 is a recognized aspect of the Th2 response in asthma patients, it may be the case that the diminished IFN-l1 response in these patients 37 contributes directly to their elevated IL-13 levels via the mechanism suggested by the present data.
Recently, another new cytokine that affects Th2 responses has been described. IL-19 expression is sensitive to IL-4 61 and is known to enhance developing Th2 responses. [62] [63] [64] IL-19 also alters the induction of human mDC, such that they display elevated IL-10 secretion with no effect on IL-12. 65 We show here that IFN-l1 upregulated mDC IL-12 secretion with a corresponding reduction of IL-10 secretion and consistently diminished the Th2 response in several experimental systems. This result complements our previously observed effect of IL-19 on mDC, where IL-10 was elevated and IL-12p70 was unaffected. 66 Thus, these two cytokines may represent a new and hitherto unexpected control mechanism over mDC. With the present description of modulation of Th1/Th2 responses by IFN-l1 against Th2 and previous complementary reports on IL-19's ability to skew Th1/Th2 responses in favor of Th2, new doors may be opening on the regulation of the Th2 response that may have subsequent impact on T-cell-dependent disorders, such as rheumatoid arthritis, psoriasis, asthma and atopic disease.
Materials and methods
Cells
Human PBMCs were isolated from anonymous buffy coats or volunteer donor peripheral blood by densitygradient centrifugation over 'Histopaque-1077' (Sigma, St Louis, MO, USA). 'Untouched' T cells were prepared from PBMC using the MACS system (Miltenyi Biotech, Auburn, CA, USA) and the 'Pan T Cell isolation kit II' (removing cells expressing CD14, CD16, CD19, CD36, CD56, CD123 and Glycophorin A). Monocytes were prepared through positive selection of CD14 þ cells present within PBMC, again using the MACS system, according to the manufacturer's instructions. DCs were created from positively selected CD14 þ monocytes through culturing in the presence of IL-4 and GM-CSF (10 ng/ml, Peprotech) for 5-7 days and were matured in the presence of LPS (100 ng/ml, Sigma) for 24 h. In some experiments, IFN-l1 was added as indicated. Cells were then washed thrice, rested for 1 h and given a further round of washing to ensure removal of LPS and cytokines before use in functional assays.
Culture conditions
Culture medium consisted of RPMI 1640 medium, 10% fetal calf serum (FCS) supplemented with penicillin at 100 IU/ml and streptomycin at 100 mg/ml (all from Sigma). For dose-response experiments, whole PBMCs were cultured in 96-well, flat-bottomed plates (2 Â 10 5 in 200 ml) for 18 h over a range of IFN-l1 concentrations (Peprotech), as shown. For all other experiments, PBMCs were cultured at 2 Â 10 6 cells in 2 ml in the presence or absence of human recombinant IFN-l1 at 1 mg/ml. For antibody-blocking experiments, cells were preincubated for 1 h with rat-anti-human-IL-10 (clone 9D7) or isotype control MAb (BD Pharmingen, San Jose, CA, USA) at a concentration of 10 mg/ml before addition of IFN-l1. In some experiments, IL-10 (Peprotech) was added to cultures at 10 ng/ml. Supernatants were harvested and frozen at À801C for later cytokine analysis by ELISA.
Whole PBMC two-way MLRs were performed in 24-well plates in a final volume of 2 ml using 1 Â 10 6 PBMCs from each of two unrelated donors. Cells and supernatants were harvested at the time points indicated for later analysis of cytokine levels. Con-A stimulations were performed in 24-well plates using 1 Â 10 6 whole PBMCs with a range of Con-A from 0-10 mg/ml in a final volume of 2 ml.
To examine the effect of IFN-l1 on the acquisition of cytokine secreting phenotype by naive Tcells, mature DCs were generated as described above, washed and seeded into 12-well plates along with naive Tcells (5 Â 10 5 naive CD4 þ T cells þ 5 Â 10 3 mDC in a final volume of 2 ml). In some experiments, antibodies and cytokines were added to the MLR at this stage to direct the cytokine-producing phenotype of the developing T cells. For Th2-biasing, IL-4 (10 ng/ml) and anti-IL-12 p70 (1 mg/ml) were added to the culture and for Th1-biasing, IL-12 p70 (10 ng/ml) and anti-IL-4 (1 mg/ml) were added. Experiments termed as 'unbiased' contained no cytokine or antibody, whereas those defined as 'Th0-type'-biased (giving rise to an intermediate T-cell cytokine-secreting phenotype based on IL-13/IFN-g levels) were induced using both anti-IL-12 and anti-IL-4. These MLRs were cultured for a total of 9 days, with 1 ml of supernatant being taken on days 3 and 6, being replaced with fresh medium containing IL-2 at 10 U/ml to expand reacting T cells. Cells were then harvested, washed twice and rested for 4 h before two more rounds of washing to remove any remaining antibody/cytokine. Cells were then resuspended into 2 ml RPMI, 10% FCS containing PMA (10 ng/ml) and ionomycin (1 mg/ml), transferred to new 12-well plates and cultured for a further 18 h. Cells and supernatant were taken for analysis to assess the development of cytokine development.
Measurement of cytokine protein
Cytokine levels within supernatants were measured using ELISA. Paired antibodies consisting of purified captured and biotinylated secondary detection antibodies purchased from BD Pharmingen were used according to the manufacturer's recommendations. Standards were purchased from Peprotech. The ELISA protocol was performed as described previously. 61 
